Zura Bio Limited (94E.F)
EUR 2.36
(0.85%)
EUR 2.36
(0.85%)
| Breakdown | 2023 | 2022 |
|---|---|---|
| Operating Cash Flow | -15.05 Million | -1.2 Million |
| Net Income | -60.56 Million | -27.33 Million |
| Depreciation & Amortization | - | - |
| Deferred income taxes | - | - |
| Stock-based compensation | 9.65 Million | 334 Thousand |
| Change in working capital | 5.11 Million | 3.54 Million |
| Other non-cash items | 30.73 Million | 22.25 Million |
| Investing Cash Flow | -8 Million | -12 Million |
| Investments in PPE | -8 Million | -12 Million |
| Acquisitions | - | - |
| Investment purchases | - | - |
| Sales/Maturities of investments | - | - |
| Other Investing Activities | -8 Million | - |
| Financing Cash Flow | 121.29 Million | 14.76 Million |
| Debt repayment | -10 Million | -7.6 Million |
| Dividends payments | - | - |
| Common Stock Repurchased | - | - |
| Common Stock Issuance | 116.4 Million | - |
| Other Financing Activities | -1.18 Million | 14.76 Million |
| Accounts receivables | - | - |
| Accounts payables | - | 288.29 Thousand |
| Inventory | - | - |
| Other working capital | 5.11 Million | 3.25 Million |
| Cash at beginning of period | 1.56 Million | 729.22 Thousand |
| Cash at end of period | 99.8 Million | 1.56 Million |
| Capital Expenditure | -8 Million | -12 Million |
| Effect of forex changes on cash | - | -729.22 Thousand |
| Net cash flow / Change in cash | 98.23 Million | 837.77 Thousand |
| Free Cash Flow | -23.05 Million | -13.2 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -10.32 Million | -7.74 Million | -60.56 Million | -8.47 Million | -8.27 Million | -34.02 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.92 Million | 2.4 Million | 9.65 Million | 2.39 Million | 2.57 Million | 2.31 Million |
| Change in working capital | 19 Thousand | -227 Thousand | 5.11 Million | 3 Million | 2.83 Million | -969 Thousand |
| Other non-cash items | 767 Thousand | - | 30.73 Million | -983 Thousand | 288 Thousand | 27.5 Million |
| Investing Cash Flow | -10 Thousand | -5 Million | -8 Million | - | -2.25 Million | -5.75 Million |
| Investments in PPE | -10 Thousand | -5 Million | -8 Million | - | -2.25 Million | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 105.25 Million | - | 121.29 Million | - | -4.12 Million | 79.76 Million |
| Debt repayment | - | - | -10 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 55.22 Million | - | 116.4 Million | - | -4.12 Million | 63.84 Million |
| Other Financing Activities | 50.03 Million | - | -1.18 Million | - | - | 15.91 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 19 Thousand | - | - | - | - | - |
| Cash at beginning of period | 89.81 Million | 99.8 Million | 1.56 Million | 103.85 Million | 112.8 Million | 43.96 Million |
| Cash at end of period | 188.44 Million | 89.81 Million | 99.8 Million | 99.8 Million | 103.85 Million | 112.8 Million |
| Capital Expenditure | -10 Thousand | -5 Million | -8 Million | - | -2.25 Million | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 98.62 Million | -9.98 Million | 98.23 Million | -4.05 Million | -8.94 Million | 68.83 Million |
| Free Cash Flow | -6.62 Million | -9.98 Million | -23.05 Million | -4.05 Million | -4.82 Million | -5.17 Million |
600250
NATL
BVCI
8467
NXFR
8938